 |
| INVITATION |
| to the OptiMiSe 2020 annual conference |
|
|
| Please consider this an invitation to join us for the upcoming OptiMiSe 2020 annual conference. |
| To register for this meeting, please sign up online at: www.sanofieducation.co.uk/optimise |
| Access code: OPTIMISE2020 |
|
|
| Patient-centric management in MS | Friday 1 – Saturday 2 May |
Millennium Gloucester Hotel Kensington London, Harrington Gardens,
South Kensington, London, SW7 4LH |
| The OptiMiSe programme, including scientific content, is an educational promotional programme organised and funded by Sanofi Genzyme. |
|
|
| Dear [recipient name] |
Following the success of previous OptiMiSe meetings, it is our pleasure to invite you to the OptiMiSe 2020 annual conference. OptiMiSe is a programme that has been empowering nurses to provide the best care for people with MS since 2016. The programme is designed by experienced nurses and provides education, skills training and resources.
OptiMiSe aims to empower you to overcome your daily challenges – from demanding conversations to working effectively with limited resources.
This 1.5 day, CPD-accredited meeting will include plenary sessions, peer-to-peer exchange, interactive workshops and learning reflections in line with NMC revalidation requirements. |
|
|
|
| Day 1 |
|
Arrivals and refreshments |
|
|
Welcome: Preparing for meaningful reflection |
|
|
Celebrating success: The impact of OptiMiSe on clinical practice |
|
|
OptiMiSe Outcomes: Collecting baseline data |
|
|
Effective information exchange: Tips and tricks for non-F2F communications |
|
|
Deepening the patient consultation: Navigating relationships |
|
|
Informed patient choice: Communicating their options |
|
|
|
Introduction to communication workshops |
|
|
Communication workshops
Focusing on effective communication, including telephone communication
and responding to patient relationships |
|
|
Making time for you: Focus on wellness |
|
|
Working across disciplines: Live interactive MDT |
|
|
Looking ahead: The OptiMiSe journey, personal reflections and Day 1 close |
|
|
|
Sharing practice: Peer-to-peer exchange |
|
|
|
| Day 2 |
|
Reflecting on the journey so far: Day 2 opening |
|
|
Making time for you: Wellness in action |
|
|
Tracking disease activity: Neurologist perspective |
|
|
Tracking disease activity: MSSN perspective – the Southampton experience |
|
|
|
Practical guide to DMT monitoring and pathway mapping: Interactive session |
|
|
Looking ahead: The OptiMiSe journey and personal reflections |
|
|
Taking the next steps: Summary and close |
|
|
|
For more information about the OptiMiSe annual conference, please contact: optimise@healthcare21.co.uk, or speak to your local Sanofi Genzyme representative.
We very much hope you will be able to attend. |
With kind regards,
|
|
Gail Clayton, Fiona Magill, Emma Matthews, Rachel Morrison, Denise Owen,
Del Thomas, Karen Vernon, Sarah White |
| The OptiMiSe Steering Committee |
|
|
| |
| You have received this email because you have previously agreed for Sanofi (including Aventis Pharma Limited, Genzyme Therapeutics Limited and/or Sanofi-Aventis Ireland Limited) to contact you by email with information about goods and services which we feel may be of interest to you. |
| Please do not reply to this email; this address is not monitored. |
 |
© 2002–2019 Sanofi.
All rights reserved |
410 Thames Valley Park, Reading, RG6 1PT |
|
If you would like more information about how Sanofi processes your personal data, please read our privacy policy. This email is intended for use by UK healthcare professionals only.
GZUK.MS.20.01.0001e | Date of preparation: February 2020
If you no longer wish to receive communication from Sanofi, you can unsubscribe here. Please note that unsubscribing will apply to unsolicited direct marketing emails only as we may still need to email you for other reasons; for example, responding to a report of an adverse event. |
LEMTRADA®  12 mg (alemtuzumab) concentrate for solution for infusion. Please refer to the Summary of Product Characteristics (SmPC) before prescribing. |
| AUBAGIO® 14 mg (teriflunomide) film-coated tablets. Please refer to the SmPC before prescribing. |
|
|
|
|
|
|
|
|